(i-BROO-tih-nib)
This page contains brief information about ibrutinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Ibrutinib is approved to treat adults with:
- Chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Chronic lymphocytic leukemia and small lymphocytic lymphoma that has a chromosome change called 17p deletion.
- Waldenström macroglobulinemia (a type of non-Hodgkin lymphoma).
Ibrutinib is also being studied in the treatment of other types of cancer and other conditions.
More About Ibrutinib
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Ibrutinib – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?
Clinical Trials Accepting Patients
Find Clinical Trials for Ibrutinib – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
